In another phase I trial for metastatic colorectal cancer (NCT03415100), locally administered NKG2D CAR-NK cell therapy resulted in a reduction in malignant ascites in two patients and a complete metabolic response in a liver lesion in a third patient, all without major adverse events [238]. Here, KLRK1 is linked to metastatic colorectal cancer.